Get started
Author

David Hays

CD8 cell PET imaging with 89-Zr-crefmirlimab berdoxam (crefmirlimab) in patients with metastatic renal cell carcinoma (mRCC) receiving checkpoint inhibitors (CPIs): Association with response and tissue CD8 expression.
2023 · Sumanta Kumar Pal, Przemyslaw Twardowski, et al. · Journal of Clinical Oncology · 5
PDF
Baseline CD8 lymph node avidity with 89-Zr-crefmirlimab in patients with metastatic renal cell carcinoma and response to IO therapy.
2024 · Peter D. Zang, Przemyslaw Twardowski, et al. · Journal of Clinical Oncology · 2
Prediction of immunotherapy response using live tumor fragments from routine clinical biopsies
2026 · David Braun, Nicholas Dana, et al. · medRxiv · 1
CD8 PET imaging with [ 89 Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate study
2026 · Michael A Postow, Peter D Zang, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
1472 Assessing the correlation between CD8 cell PET Imaging with 89-Zr-Crefmirlimab Berdoxam and CD8 cell immunohistochemistry in patients with advanced cancer receiving immunotherapy
2022 · Michael Postow, Audrey Mauguen, et al. · 1
PDF
Abstract CT132: iPREDICT trial: A phase IIb, open label study of 89Zr-Crefmirlimab Berdoxam PET/CT in subjects with selected advanced malignancies (melanoma, merkel cell, renal cell and non-small cell lung cancers), scheduled to receive standard-of-care immunotherapy, to predict response to therapy
2022 · Kim Margolin, David Hays, et al. · Cancer Research · 1
Cytokine data supporting article title: Prediction of immunotherapy response using live tumor fragments from routine clinical biopsies
2026 · David Braun, Nicholas Dana, et al. · Figshare
iPREDICT: Phase II study of CD8 PET in patients with immunoresponsive solid tumors—Imaging characteristics and correlation with RECIST response.
2026 · Kim Allyson Margolin, Kristin Schmiedehausen, et al. · Journal of Clinical Oncology
Works count: 8
Citation count: 11
H-index: 2
I10-index:
Year
Topic
Type